Actinogen Medical Limited (ATGGF)
Actinogen Medical Limited
109 Pitt Street
Suite 901 Level 9
Sydney, NSW 2000
Australia
61 2 8964 7401
https://www.actinogen.com.au
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D. | MD, CEO & Director | 340.56k | N/D | 1960 |
| Dr. Dana C. Hilt M.D. | Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board | 255.13k | N/D | 1953 |
| Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D. | Head of Clinical Pharmacology & Lead Physician and Depression | 62.64k | N/D | N/D |
| Mr. William Edward Souter BCom, IPAA, LLB (Adel) | Chief Financial Officer | N/D | N/D | N/D |
| Mr. Michael Roberts | Head of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Dr. Fujun Li Ph.D. | Head of Manufacturing | N/D | N/D | N/D |
| Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. | Company Secretary | N/D | N/D | 1963 |
Descripción
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, depression with cognitive impairment, Alzheimer's disease, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Gestión corporativa
La calificación ISS Governance QuickScore de Actinogen Medical Limited a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
